DOCSLIB.ORG

New Horizons Forum

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
New Horizons Forum Speeding the development of new therapies and diagnostics for glaucoma patients New Horizons Forum Friday, February 9, 2018 Palace Hotel, San Francisco, CA © Aerie Pharmaceuticals, Inc. Irvine, CA 92614 Follow the meeting on Twitter: #Glaucoma360 MLR-0002 Glaucoma Research Foundation thanks the following sponsors WELCOME for their generous support of Glaucoma 360 PLATINUM It is our sincere pleasure to welcome you to the 7th Annual Glaucoma 360: New Horizons Forum, hosted by Glaucoma Research Foundation. This important meeting provides a unique opportunity to bring together leaders in medicine, science, industry, venture capital, and the FDA to discuss emerging ideas in glaucoma and encourage collaboration to accelerate their development for clinical use. Since its establishment in 2012, this annual forum continues to grow and provide the ultimate opportunity to highlight important advances and facilitate networking between these essential groups. As a result, there are now more effective therapies and diagnostic tools in clinical practice today to help doctors manage the disease more effectively. But, unmet medical needs remain in glaucoma. Glaucoma Research Foundation is resolute in its mission to preserve vision and continue its role as a catalyst in the advancement of research towards new treatments and a cure. SILVER Glaucoma 360 would not be possible without the generous and selfless contributions of so many including: members of our Advisory Board, Program and Steering Committees who have volunteered their time to build an outstanding agenda; our dedicated sponsors who have helped to underwrite this event; our speakers, presenters, and panelists who are ready to share their expertise and unique perspectives; our attendees; the support of our Board of Directors and staff at Glaucoma Research Foundation; and the hard working team at The Palace Hotel. Over the past seven years, the field has grown substantially and we are honored and grateful to all of you, for your ongoing dedication to helping patients. Because of your commitment, we now have more options to care for patients than ever before. All proceeds from Glaucoma 360 events will support Glaucoma Research Foundation’s sight-saving endeavors such as the Catalyst for a Cure, a unique collaborative approach to uncover new diagnostic and treatment options for glaucoma. Thank you for your wonderful partnership in our mission. Together, we can truly make a difference in the lives of people living with glaucoma. BRONZE Akorn, Inc. IRIDEX Corporation Optos, Inc. Beaver-Visitec International Lumenis Vision Optovue, Inc. Adrienne L. Graves, PhD Andrew G. Iwach, MD Co-Founder and Co-Chair, Glaucoma 360 Co-Founder and Co-Chair, Glaucoma 360 Ellex Mobius Therapeutics, LLC Quantel Medical Director, Glaucoma Research Foundation Board Chair, Glaucoma Research Foundation Haag-Streit USA Nidek Inc. Shire Icare USA, Inc. Ophthalmic Mutual Insurance Sight Sciences, Inc. Company Wi-Fi sponsored by Santen Inc., Network: Palace Meetings, Password: 2018G360 2018 New Horizons Forum 1 PROGRAM Follow the meeting on Twitter: #Glaucoma360 7:30 – 8:00 am REGISTRATION, BREAKFAST AND EXHIBITS Panelists • Allergan, Inc., Jag Dosanjh, Senior Vice President, Eye Care • Glaukos Corporation, Chris M. Calcaterra, Chief Operating Officer • Heidelberg Engineering, Kfir Azoulay, MBA, Head of Strategy 8:00 – 8:06 am WELCOME AND OPENING REMARKS • Johnson & Johnson Vision, Jane Rady, Vice President, Business Development, Surgical Adrienne L. Graves, PhD and Andrew G. Iwach, MD • New World Medical, Rafael Chan, Chief Commercial Officer Co-Founders and Co-Chairs, Glaucoma 360 • Santen Inc., Ram Palanki, PharmD, Senior Vice President of Commercial, Americas • Carl Zeiss Meditec, Inc., Angelo Rago, Global Head, Ophthalmic Diagnostics 8:06 – 8:32 am OPENING KEYNOTE ADDRESS — Drs. Henry and Frederick Sutro Memorial Lecture Interventional Glaucoma: The Why, The Who, and The How 10:11:26 – 11:31 am INDUSTRY SPOTLIGHT — Allergan, Inc. Speaker Iqbal Ike K. Ahmed, MD, FRCSC Speaker Jag Dosanjh Medical Director, Prism Eye Institute; Associate Professor of Ophthalmology, University of Toronto; Senior Vice President, Eye Care Clinical Professor of Ophthalmology, University of Utah 11:31 – 12:09 pm FUNDING INNOVATIONS: VENTURE CAPITAL PANEL DISCUSSION MORNING CATALYST Moderators Emmett Cunningham, Jr., MD, PhD, MPH Joel S. Schuman, MD, FACS Partner, Clarus Ventures Professor and Chairman of Ophthalmology, NYU Langone Medical Center, NYU School of Medicine; Andrew Gitkin Professor of Electrical and Computer Engineering, NYU Tandon School of Engineering Managing Director and Head of West Coast Biotechnology Banking, Piper Jaffray Panelists • Juliet Bakker, Managing Director and Founder, Longitude Capital • William J. Link, PhD, Founder, Flying L Partners, Managing Director, Versant Ventures 8:34 – 9:09 am NEW HORIZONS IN VIRTUAL REALITY • Heather Preston, MD, Partner and Managing Director, TPG Biotech Moderators Andrew D. Huberman, PhD • Christy Shaffer, PhD, Partner, Hatteras Venture Partners Associate Professor of Neurobiology and Ophthalmology, Stanford University; Member, Catalyst for a Cure Biomarker Initiative Felipe Medeiros, MD, PhD Professor of Ophthalmology, Vice Chair, Technology, Duke University School of Medicine 10:12:09 – 12:14 pm INDUSTRY SPOTLIGHT — Aerie Pharmaceuticals, Inc. Presenting • nGoggle, Inc., Felipe Medeiros, MD, PhD, Professor of Ophthalmology, Vice Chair, Technology, Duke University School of Medicine Speaker Thomas A. Mitro Companies • Vivid Vision, Ben Backus, PhD, Chief Science Officer President and Chief Operating Officer 9:09 – 9:14 am INDUSTRY SPOTLIGHT — Santen Inc. Speaker Ram Palanki, PharmD 12:14 – 1:10 pm NETWORKING BUFFET LUNCHEON Senior Vice President of Commercial, Americas 9:14 – 10:21 am NEW HORIZONS IN GLAUCOMA DEVICES AFTERNOON CATALYST Moderators E. Randy Craven, MD George A. Cioffi, MD Chief, Wilmer Eye Institute – Bethesda; Associate Professor of Ophthalmology, Johns Hopkins University School of Medicine Edward S. Harkness Professor and Chairman, Columbia University College of Physicians and Surgeons; Eydie G. Miller-Ellis, MD Ophthalmologist-in-Chief, New York-Presbyterian Hospital/Columbia University Medical Center Professor of Clinical Ophthalmology, Scheie Eye Institute, University of Pennsylvania Presenting • Alcon, a Novartis Division, Richard A. Lewis, MD, Co-Founder, Sacramento Eye Consultants 1:12 – 2:30 pm NEW HORIZONS IN GLAUCOMA DRUG DELIVERY Companies • Allergan, Inc., Michael Robinson, MD, Vice President and Therapeutic Area Head, Anterior Segment and Consumer Eye Care Moderators James D. Brandt, MD • Camras Vision, Ray Krauss, Chief Executive Officer Director of Glaucoma Service, Professor of Ophthalmology and Visual Science, UC Davis • Ivantis, Inc., Brett A. Trauthen, Chief Scientific Officer Anne L. Coleman, MD, PhD • LumiThera, Clark Tedford, PhD, President and Chief Executive Officer Vice Chair of Department of Ophthalmology, Stein Eye Institute, Frances and Ray Stark Foundation Professor of Ophthalmology, • MicroOptx, Chris Pulling, Chief Executive Officer Stein Eye Institute of the David Geffen School of Medicine, University of California, Los Angeles, Professor of Epidemiology, • Santen Inc., Leonard Pinchuk, PhD, DSc (h.c.), NAE, Founder and Chief Scientific Officer, InnFocus, Inc., a Santen company Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles • Sight Sciences, Inc., Steven Vold, MD, Founder and Chief Executive Officer, Vold Vision; Chief Medical Editor,Glaucoma Today Presenting • Eyenovia, Inc., Shan Lin, MD, Professor of Clinical Ophthalmology, Director, Glaucoma Service, and Director Glaucoma Companies Fellowship Program, Department of Ophthalmology, UCSF • Glaukos Corporation, Jeff Wells, PharmD, Senior Vice President, Clinical, Regulatory and Quality 10:21 – 10:51 am BREAK, EXHIBITS AND NETWORKING OPPORTUNITY • Graybug Vision, Inc., Jeffrey L. Cleland, PhD, President and Chief Executive Officer • Mati Therapeutics, Christopher A. Muller, Chief Commercial Officer • Ocular Therapeutix, Michael H. Goldstein, MD, MBA, Chief Medical Officer • Otero Therapeutics, Morgan V. Fedorchak, PhD, President and Chief Technology Officer; Assistant Professor of Ophthalmology, 10:51 – 11:26 am INDUSTRY PANEL DISCUSSION: GLAUCOMA DEVICES Bioengineering and Clinical & Translational Sciences, University of Pittsburgh Moderators Malik Kahook, MD • Retroject, Inc., Molly Walsh, MD, Founder and Chief Executive Officer Slater Family Endowed Chair of Ophthalmology, Vice Chair, Clinical and Translational Research; • UCSF, Tejal Desai, PhD, Professor and Chair, Department of Bioengineering and Chief, Glaucoma Service and Director, Glaucoma Fellowship, Professor of Ophthalmology, University of Colorado Therapeutic Sciences, School of Pharmacy, UCSF Steven Vold, MD • USC, Mark S. Humayun, MD, PhD, Cornelius J. Pings Chair in Biomedical Sciences, Founder and Chief Executive Officer, Vold Vision; Chief Medical Editor,Glaucoma Today Professor of Ophthalmology, Biomedical Engineering and Integrative Anatomical Sciences, Director of the Institute for Biomedical Therapeutics and Co-Director of the USC Roski Eye Institute 2 Glaucoma Research Foundation 2018 New Horizons Forum 3 PROGRAM (continued) LEADERSHIP 2:30 – 2:35 pm INDUSTRY SPOTLIGHT — Novartis Alcon Pharmaceuticals Speaker Melissa Liew, MD filtering surgery, application of optical coherence tomography in glaucoma, Vice President and US Medical Head of Ophthalmology THOMAS
Load more

Recommended publications
  • Anesthesia for Eye Surgery
    Anesthesia for Eye Surgery Having a surgery can be stressful. We would like to provide you the following information to help you prepare for your eye surgery. Eye surgeries are typically done under topical or local anesthesia with or without mild sedation. Topical Anesthesia This is administered via special eye drops by a preoperative nurse. Local Anesthesia This is administered via injection by an ophthalmologist. Your ophthalmologist will inject local anesthesia to the eye that is to undergo the operation. During the injection, you will be lightly sedated. In the operating room During the procedure it is very important that you remain still. This is a very delicate surgery; any abrupt movement can hinder a surgeon’s performance. If you have any concerns during the surgery, such as pain, urge to cough or itching, please let us know immediately. Typically, patients are not heavily sedated for this type of procedure. Therefore, it is normal for patients to feel pressure around their eyes, but not pain. In order to maintain surgical sterility, your face and body will be covered with a sterile drape. You will be given supplemental oxygen to breathe. An anesthesia clinician will continue to monitor your vital signs for the duration of the procedure. The length of the procedure usually ranges from 10 minutes to 30 minutes. In the recovery room After surgery, you will be brought to the recovery room. A recovery room nurse will continue to monitor your vital signs for the next 20 to 30 minutes. It is important that you do not drive or operate any machinery for the next 24 hours.
    [Show full text]
  • Table of Contents
    Leadership Development Program Project Abstracts Table of Contents LDP XXII, CLASS OF 2020 GRADUATES Name/Society/Project Page John J. Chen, MD, PhD 1 North American Neuro-Ophthalmology Society Project: The Neuro-Ophthalmology career path: misconceptions and barriers to recruitment Jeremy D. Clark, MD 2 Kentucky Academy of Eye Physicians and Surgeons Project: The Web of Innovation: Silent Auction Benefitting Political Action funds in Kentucky Gennifer J. Greebel, MD 3 New York State Ophthalmological Society Project: Inspiring Professional Aspirations in Adolescents with Low Vision Mark A. Greiner, MD 4 Eye Bank Association of America Project: Revisiting Eye Banking Medical Standards To Accommodate Emerging Technologies Jennifer F. Jordan, MD 5 North Carolina Society of Eye Physicians and Surgeons Project: Advocacy Exposure for North Carolina Ophthalmologists in Training Kapil G. Kapoor, MD 6 Virginia Society of Eye Physicians and Surgeons Project: Unwrapping Virginia Bill 506B Erin Lichtenstein, MD 7 Maine Society of Eye Physicians and Surgeons Project: Bringing Ophthalmology Residents to Maine Jennifer L. Lindsey, MD 8 Association of Veterans Affairs Ophthalmologists Project: Illuminating the Path to Advocacy for Veterans Affairs Ophthalmologists Donald A. Morris, DO 9 American Osteopathic College of Ophthalmology Project: Single Accreditation of Ophthalmology residencies is here. What is the next step? Lisa Nijm, MD, JD 10 Women in Ophthalmology Project: Implementing a Clinical Trials Training Program to Increase Diversity of Primary Investigators Involved in Ophthalmic Research LDP XXII, CLASS OF 2020 GRADUATES (cont’d) Name/Society/Project Page Roma P. Patel, MD, MBA 11 California Academy of Eye Physicians and Surgeons Project: Increasing Membership Value to our CAEPS Members Jelena Potic, MD, PhD 12 European Society of Ophthalmology Project: Harmonization of Surgical Skills Standards for Young Ophthalmologists across Europe Pradeep Y.
    [Show full text]
  • Laser Vision Correction Surgery
    Patient Information Laser Vision Correction 1 Contents What is Laser Vision Correction? 3 What are the benefits? 3 Who is suitable for laser vision correction? 4 What are the alternatives? 5 Vision correction surgery alternatives 5 Alternative laser procedures 5 Continuing in glasses or contact lenses 5 How is Laser Vision Correction performed? 6 LASIK 6 Surface laser treatments 6 SMILE 6 What are the risks? 7 Loss of vision 7 Additional surgery 7 Risks of contact lens wear 7 What are the side effects? 8 Vision 8 Eye comfort 8 Eye Appearance 8 Will laser vision correction affect my future eye health care? 8 How can I reduce the risk of problems? 9 How much does laser vision correction cost? 9 2 What is Laser Vision Correction? Modern surgical lasers are able to alter the curvature and focusing power of the front surface of the eye (the cornea) very accurately to correct short sight (myopia), long sight (hyperopia), and astigmatism. Three types of procedure are commonly used in If you are suitable for laser vision correction, your the UK: LASIK, surface laser treatments (PRK, surgeon will discuss which type of procedure is the LASEK, TransPRK) and SMILE. Risks and benefits are best option for you. similar, and all these procedures normally produce very good results in the right patients. Differences between these laser vision correction procedures are explained below. What are the benefits? For most patients, vision after laser correction is similar to vision in contact lenses before surgery, without the potential discomfort and limitations on activity. Glasses may still be required for some activities after Short sight and astigmatism normally stabilize in treatment, particularly for reading in older patients.
    [Show full text]
  • Curriculum Vitae
    CURRICULUM VITAE NOMBRE: Jorge Luciano Alió y Sanz SITUACIÓN PROFESIONAL: Catedrático de Oftalmología. Universidad Miguel Hernández, Elche (Alicante). Director Científico, Corporación Oftalmológica Vissum-Valcasado S.A. DIRECCION: Calle Cabañal, 1 - Edificio VISSUM- 03016 Alicante, Tfno: 965-15-00-25; Fax: 965-15-15- 01; e-mail: [email protected] ; Web: www.vissum.com ; Web Dr. Alió: www.doctoralio.com TITULACION: - Licenciado en Medicina y Cirugía, Universidad Complutense de Madrid, 1976.( Sobresa- liente). - Doctor en Medicina, Universidad Complutense de Madrid, 1980. (Sobresaliente “Cum Laude”). CARRERA ASISTENCIAL: - Médico Residente por Oposición (MIR), Departamento de Oftalmología, Clínica de la Concepción, Fundación Jiménez Díaz. Universidad Autónoma de Madrid (1977-1980). - Médico Adjunto por Oposición, Hospital “Miguel Servet” de Zaragoza (1980-1982). - Jefe de Sección por Oposición, Hospital General Universitario de Salamanca (1982- 1986). - Fundador del Instituto Oftalmológico de Alicante (1995). Esta Institución se encuentra actualmente vinculada a efectos docentes e investigadores a la Universidad Miguel Her- nández, manteniendo convenios de investigación con otras universidades e instituciones públicas, como el Instituto Carlos III (Madrid), Universidad de Alicante, Universidad de www.doctorjorgealio.com 1 Valladolid, Louisiana State University (New Orleans, USA), Ophthalmic Research Institute (El Cairo, Egypt) y Universidad de El Cairo (Egypt), Universidad de La Habana (Cuba) y Universidad Politécnica de Valencia. Es centro consultor acreditado por la Consellería de Sanidad de la Generalitat Valenciana. Ha alcanzado así mismo las acreditaciones de calidad sanitaria de la U.S. Joint Commission on Accreditation of Healthcare Organi- zations (USA) (1999) y ISO 9001 (2001). Es el único centro de cirugía ambulatoria y el primer centro oftalmológico de la Unión Europea que ha alcanzado ambas calificaciones de calidad hasta la fecha.
    [Show full text]
  • Root Eye Dictionary a "Layman's Explanation" of the Eye and Common Eye Problems
    Welcome! This is the free PDF version of this book. Feel free to share and e-mail it to your friends. If you find this book useful, please support this project by buying the printed version at Amazon.com. Here is the link: http://www.rooteyedictionary.com/printversion Timothy Root, M.D. Root Eye Dictionary A "Layman's Explanation" of the eye and common eye problems Written and Illustrated by Timothy Root, M.D. www.RootEyeDictionary.com 1 Contents: Introduction The Dictionary, A-Z Extra Stuff - Abbreviations - Other Books by Dr. Root 2 Intro 3 INTRODUCTION Greetings and welcome to the Root Eye Dictionary. Inside these pages you will find an alphabetical listing of common eye diseases and visual problems I treat on a day-to-day basis. Ophthalmology is a field riddled with confusing concepts and nomenclature, so I figured a layman's dictionary might help you "decode" the medical jargon. Hopefully, this explanatory approach helps remove some of the mystery behind eye disease. With this book, you should be able to: 1. Look up any eye "diagnosis" you or your family has been given 2. Know why you are getting eye "tests" 3. Look up the ingredients of your eye drops. As you read any particular topic, you will see that some words are underlined. An underlined word means that I've written another entry for that particular topic. You can flip to that section if you'd like further explanation, though I've attempted to make each entry understandable on its own merit. I'm hoping this approach allows you to learn more about the eye without getting bogged down with minutia ..
    [Show full text]
  • Cme Reviewarticle
    Volume 58, Number 2 OBSTETRICAL AND GYNECOLOGICAL SURVEY Copyright © 2003 by Lippincott Williams & Wilkins, Inc. CME REVIEWARTICLE 5 CHIEF EDITOR’S NOTE: This article is part of a series of continuing education activities in this Journal through which a total of 36 AMA/PRA category 1 credit hours can be earned in 2003. Instructions for how CME credits can be earned appear on the last page of the Table of Contents. Ocular Changes in Pregnancy Robert B. Dinn, BS,* Alon Harris, MSc, PhD† and Peter S. Marcus, MD‡ *Fourth Year Medical Student, Indiana University School of Medicine; †Professor, Glaucoma Research and Diagnostic Center, Departments of Ophthalmology and Physiology, Indiana University School of Medicine; and ‡Assistant Clinical Professor, Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana Visual changes in pregnancy are common, and many are specifically associated with the preg- nancy itself. Serous retinal detachments and blindness occur more frequently during preeclampsia and often subside postpartum. Pregnant women are at increased risk for the progression of preexisting proliferative diabetic retinopathy, and diabetic women should see an ophthalmologist before pregnancy or early in the first trimester. The results of refractive eye surgery before, during, or immediately after pregnancy are unpredictable, and refractive surgery should be postponed until there is a stable postpartum refraction. A decreased tolerance to contact lenses also is common during pregnancy; therefore, it is advisable to fit contact lenses postpartum. Furthermore, preg- nancy is associated with a decreased intraocular pressure in healthy eyes, and the effects of glaucoma medications on the fetus and breast-fed infant are largely unknown.
    [Show full text]
  • Anesthesia Management of Ophthalmic Surgery in Geriatric Patients
    Anesthesia Management of Ophthalmic Surgery in Geriatric Patients Zhuang T. Fang, M.D., MSPH Clinical Professor Associate Director, the Jules Stein Eye Institute Operating Rooms Department of Anesthesiology and Perioperative Medicine David Geffen School of Medicine at UCLA 1. Overview of Ophthalmic Surgery and Anesthesia Ophthalmic surgery is currently the most common procedure among the elderly population in the United States, primarily performed in ambulatory surgical centers. The outcome of ophthalmic surgery is usually good because the eye disorders requiring surgery are generally not life threatening. In fact, cataract surgery can improve an elderly patient’s vision dramatically leading to improvement in their quality of life and prevention of injury due to falls. There have been significant changes in many of the ophthalmic procedures, especially cataract and retinal procedures. Revolutionary improvements of the technology making these procedures easier and taking less time to perform have rendered them safer with fewer complications from the anesthesiology standpoint. Ophthalmic surgery consists of cataract, glaucoma, and retinal surgery, including vitrectomy (20, 23, 25, or 27 gauge) and scleral buckle for not only retinal detachment, but also for diabetic retinopathy, epiretinal membrane and macular hole surgery, and radioactive plaque implantation for choroidal melanoma. Other procedures include strabismus repair, corneal transplantation, and plastic surgery, including blepharoplasty (ptosis repair), dacryocystorhinostomy (DCR)
    [Show full text]
  • Anaesthesia for Eye Surgery Eye Surgery Can Be Performed Under Eye Block, Topical Anaesthesia Or General Anaesthesia
    Anaesthesia for eye surgery Eye surgery can be performed under eye block, topical anaesthesia or general anaesthesia. The choice of anaesthesia depends on the patient, type of surgery and the preference of the eye surgeon and patient. Eye blocks Eye blocks are commonly used for eye surgery and involve one or two injections of local anaesthetic around the eye. Once the local anaesthetic drug begins to work, usually in around 10 minutes, the patient will not be able to see out of the eye or move it and surgery may begin. After the surgery, the eye is covered with a patch and is reviewed the next day. Reaction to local anaesthetic drugs is rare; however, it is not uncommon for the white part of the eye, the conjunctiva, to become swollen and red. The risks of the block include eye perforation (less than 1 per cent) and bleeding into the eye (less than 1 per cent). Topical anaesthesia Topical anaesthesia is commonly used in patients who are unable to have an eye block or in rare cases where the eye block fails to provide adequate anaesthesia and analgesia. Cataract surgery can be performed under topical anaesthesia using local anaesthetic eye drops, although this does not result in the same surgical operating conditions that can be achieved with an eye block. From a medical point of view, the patient should be able to lie flat. Patients with significant heart failure or respiratory disease may not be able to do so. General anaesthesia General anaesthesia involves the patient being put into a medication-induced state which, when deep enough, means that the patient will not respond to pain and includes changes in breathing and circulation.
    [Show full text]
  • Eurotimes 11-1 1-20
    10 years By Nick Lane PhD Pioneers Past and Present – But where are the boundaries of the justifiable? heir names justly echo down the halls Elder, his colleagues walked out of early example was the supplanting of horse- “I don’t think for a moment that we’re Tof fame of ophthalmology – Sir presentations; the very concept of IOL drawn carriages by cars; there were many going to see the end of LASIK or corneal Harold Ridley, Peter Choyce, Cornelius implantations was openly repudiated, and people at the time who could see no refractive surgery in general, but as the Binkhorst, Edward Epstein, Svyatoslav dismissed by the AAO as “not sufficiently advantages of cars over horses,” Dr Fine new generations of accommodating IOLs Fyodorov, Charles Kelman, Benedetto proven for use in the US”. Ridley spent told EuroTimes. come into their own, we’re likely to see Strampelli, José Barraquer, Luis Ruiz,Theo years terrified that his early failures would Of course pioneers need more than just more and more people in their fifties and Seiler, Ioannis Pallikaris, to take just a few. come back to haunt him through the vision to succeed; they also need the sixties opting for lens exchange, maybe Their techniques transformed the world courts. In Barcelona, in 1970, Joachim ability to see a technical way through the even before they’ve developed the first and restored sight for millions. But had it Barraquer was forced to explant half of problem, to convert their vision into signs of a cataract.This is not really a not been for their failures, the successes the anterior IOLs that he had implanted in action.And they need to be able to get it technical leap, at least not surgically – it is of today might never have been possible.
    [Show full text]
  • Laser Vision Correction: a Tutorial for Medical Students
    Laser Vision Correction: A Tutorial for Medical Students Written by: Reid Turner, M4 Reviewed by: Anna Kitzmann, MD Illustrations by: Steve McGaughey, M4 November 29, 2011 1. Introduction Laser vision correction is the world’s most popular elective surgery with roughly 700,000 LASIK procedures performed in the U.S. each year (AAO, 2008). Since refractive errors affect half of the U.S. population 20 years of age and older, it comes as no surprise that many people are turning to laser vision correction to obtain improved vision (Vitale et al. 2008). Due to its popularity, medical students will inevitably be asked by patients, family, and friends about refractive eye surgery. It is important to have a basic understanding of laser vision correction, outcomes, and associated risks. The goal of laser vision correction is to decrease dependence on glasses and contact lenses by focusing light more effectively on the retina. While there are a number of different surgeries used to achieve this result, this tutorial will focus specifically on laser vision correction, which consists of laser in situ keratomileusis (LASIK) and photorefractive keratectomy (PRK). In the U.S., LASIK comprises about 85% of the laser vision correction market with PRK making up the other 15% (ISRS 2009). The cost of surgery varies in price from hundreds to thousands of dollars and is not covered by insurance, similar to cosmetic surgery. Laser vision correction is regarded as highly effective with studies showing 94% of patients achieving uncorrected visual acuity of 20/40 or better at 12 months (Salz et al. 2002), which is the visual acuity needed to drive without corrective lenses in most states.
    [Show full text]
  • History of Cataract Surgery
    History of Cataract Surgery A cataract is a clouding of the normally clear lens of the eye and can be addressed through a procedure that removes the affected lens and replaces it with a manmade lens known as an intraocular lens or IOL.1 Associated with improvements in vision, overall health, and cognitive and emotional well-being,2 cataract surgery is a safe and effective procedure1 and is the most commonly performed surgery in the world.3 One of the oldest surgical procedures known, cataract surgery was first documented in the fifth century BC.4 1747 French ophthalmologist Jacques Daviel is credited 1998 Toric IOLs are rolled out to correct astigmatism. Toric with the first Extracapsular Cataract Extraction, a IOLs have different powers in different meridians of the technique that uses a small incision to remove the lens and lens to correct the asymmetric power of the eye that is minimize the wound.5,6 characteristic of astigmatism.10 1753 London surgeon Samuel Sharp performs the first 2004 Aspheric IOLs, which closely match the shape and optical Intracapsular Cataract Extraction, a technique that quality of the eye’s natural lens, are introduced for sharper uses a large incision to remove the entire natural vision — especially in low light conditions and when the lens and capsule.7 pupil is dilated.11 1949 Intraocular lenses, manmade lenses made of 2010 Femtosecond laser is cleared by the FDA for cataract polymethylmethacrylate, are introduced by Sir Harold surgery.12 The femtosecond laser replaces or supports Ridley in London.8 Previously,
    [Show full text]
  • Wills Eye Manual 3Ed.Pdb
    The Wills Eye Manual, 3rd Edition MedScut ISilo v1.0 CONTENTS Frontmatter CHAPTER 1 DIFFERENTIAL DIAGNOSIS OF OCULAR SYMPTOMS CHAPTER 2 DIFFERENTIAL DIAGNOSIS OF OCULAR SIGNS CHAPTER 3 TRAUMA 3.1 Chemical Burn 3.2 Corneal Abrasion 3.3 Corneal and Conjunctival Foreign Bodies 3.4 Conjunctival Laceration 3.5 Eyelid Laceration 3.6 Traumatic Iritis 3.7 Hyphema and Microhyphema 3.8 Commotio Retinae 3.9 Traumatic Choroidal Rupture 3.10 Orbital Blow-Out Fracture 3.11 Traumatic Retrobulbar Hemorrhage 3.12 Intraorbital Foreign Body 3.13 Corneal Laceration 3.14 Ruptured Globe and Penetrating Ocular Injury 3.15 Intraocular Foreign Body 3.16 Traumatic Optic Neuropathy CHAPTER 4 CORNEA 4.1 Superficial Punctate Keratitis (SPK) 4.2 Dry-eye Syndrome 4.3 Filamentary Keratopathy 4.4 Exposure Keratopathy 4.5 Neurotrophic Keratopathy 4.6 Recurrent Corneal Erosion 4.7 Thermal/Ultraviolet Keratopathy 4.8 Thygeson’s Superficial Punctate Keratopathy 4.9 Phlyctenulosis 4.10 Pterygium/Pingueculum 4.11 Band Keratopathy 4.12 Infectious Corneal Infiltrate/Ulcer 4.13 Fungal Keratitis 4.14 Acanthamoeba 4.15 Herpes Simplex Virus 4.16 Herpes Zoster Virus (HZV) 4.17 Contact Lens–related Problems 4.18 Contact Lens–induced Giant Papillary Conjunctivitis 4.19 Interstitial Keratitis 4.20 Peripheral Corneal Thinning 4.21 Dellen 4.22 Staphylococcal Hypersensitivity 4.23 Keratoconus 4.24 Corneal Dystrophies 4.25 Fuchs’ Endothelial Dystrophy 4.26 Wilson’s Disease (Hepatolenticular Degeneration) 4.27 Corneal Graft Rejection 4.28 Aphakic Bullous Keratopathy Pseudophakic Bullous
    [Show full text]